#AACR26 highlights #CommunityOnc:
★★★Same topic zoldonrasib · 18 peopledaraxonrasibROS1#COMMUNITYONC#CM77T#TRUST#MEDX1431 views69 likes23 reposts1 reply
ESMO Congress 2026
October 23–27, 2026 · Madrid · 2669 items
zoldonrasib
0 people · 0 posts
Floor
x.com@ Anirban Maitra@Aiims1742 Zoldonrasib Deemed Safe, Effective in KRAS G12D-mutant #LungCancer
Oriol Mirallas MD@DrMirallas Stephen V Liu, MD@StephenVLiu Young Kwang Chae, MD, MPH, MBA@youngkwangchae Targeting the "undruggable" KRAS G12D just got a major boost at #AACR26!
LUNGevity Foundation@LUNGevity LUNGevity Foundation@LUNGevity AACR@AACR Stephen V Liu, MD@StephenVLiu Moffitt Cancer Center@MoffittNews Happening now at #AACR26 Clinical Trials Plenary: Jonathan Riess, MD (
Oncology Tube@oncologytube Stephen V Liu, MD@StephenVLiu Arnav Mehta@arnavmehta3 Incredibly clean safety profile for Zoldonrasib (KRAS G12D)!
x.com@ KRAS G12D mutations remain an unmet need in #NSCLC.
cancer_navi@cancer_navi Oncology Tube@oncologytube Paul H, PharmD, RPH@phsiao4 Lung Cancers Today@Lung_Cancers AACR@AACR MedPage Today@medpagetoday Silas Inman@SilasInman Zoldonrasib Displays Early Safety, Efficacy in Pretreated KRAS G12D–Mutated NSCLC
Ben Fidler@BentheFidler ICYMI: #AACR26: Revolution’s next prospect, Merck’s reveal and a lung cancer battle
Ben Fidler@BentheFidler AACR 2026: Revolution’s next prospect, Merck’s reveal and a lung cancer battle
Raffaele Di Giacomo, PhD@sciqst